Over the past three weeks, we have been sharing a special feature from Dr. Altamash Shaikh on the unique situation of diabetes in India. We have looked at the reasons, challenges, and causes for the rapid increase in diabetes in the second most populated country in the world. This week, …

Woman, type 1 diabetes, 63 years of age. Well-educated diabetes wise. Reached out to me saying: "HELP!! Normally I take 10 units of Toujeo at 9 pm. I did that last night. This morning I meant to take an additional 2 units because I'm not getting any exercise due to a knee injury. By mistake I took my usual dose of 10 units." Before I read the rest of her email, I thought, I know her. She knows what to do. She wears a CGM, she’ll be watching that. Then I read on...

Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 4, the conclusion of this Exclusive Interview, Dr. Shaikh gives his thoughts on solving the diabetes problem in the Indian community.

In this week's Homerun Slides, the ratios of the adverse events in patients and their tolerability of the placebo vs empagliflozin.

PI-3 kinase pathways: regulation of metabolism and gene expression: Signal transduction for insulin’s metabolic effects also diverges from insulin receptor substrate proteins and proceeds via the PI-3 kinase pathway. The first committed step involves type 1A PI-3 kinase, a heterodimer consisting of a p85 regulatory subunit and a p110 catalytic subunit. In quiescent cells, the regulatory subunit maintains a state of low activity for the catalytic subunit.